SteadySharesSteadyShares
The market
MarketsDiscover
Follow the money
Smart MoneyPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
Closed
SteadySharesMarketsDiscoverSmart MoneyMy WealthPoliticiansCryptoNews
/
DiscoverDHR
HealthcareNYSEUSD

Danaher Corp.

$001234567890012345678900123456789.0012345678900123456789+13.1%
52w low (est.) $163.77$258.55 52w high (est.)
Peers
Market data
Market cap
$140.88B
52-week range
$160.93 – $242.80
Beta (vs market)
0.82
Sector
Healthcare
Valuation
P/E ratio
38.6x
DCF fair value
$119.71
Margin of safety
-41.6%
Forward P/E
21.5x
PEG ratio
1.22
Dividend yield
0.82%
Quality & efficiency
Moat score
65/100
Return on equity
7.1%
Profit margin
14.9%
Debt / equity
0.37
Growth & analysts
Revenue growth (YoY)
+3.7%
Analyst target
$242.26
Target upside
+18.2%
Analysts covering
23

About Danaher Corp.

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Valuation

ValueGrowthProfitHealthIncome33QUALITY
Overall Rating
40
Reduce
Reduce
Moat Score65
DCF Intrinsic Value
$119.71-41.6% downside

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
$140.88B
P/E Ratio
38.6
Dividend Yield
0.82%
Revenue Growth
+3.7%
Profit Margin
14.9%
ROE
7.1%
Debt / Equity
0.37
Beta
0.82
vs Healthcare sector:P/E 39 vs 28 Moat 65 vs 7Yield 0.82% vs 0.3%

Statistics

Similar Stocks · Healthcare

LLY73
$920.00+0.7%
AZN.L72
£105.20+0.6%
UNH71
$492.10+1.6%
JNJ70
$146.20-0.2%

Latest News · DHR